Trials / Unknown
UnknownNCT03258047
Novel Autologou CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- First Affiliated Hospital of Zhejiang University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
It's a single arm, open label prospective study, in which the safety and efficacy of autologous CAR-T are evaluated in refractory/relapsed B cell lymphoma patients. Abbreviation: CAR-T: Chimeric Antigen Receptor T-Cell Immunotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| COMBINATION_PRODUCT | CAR-T | CAR-T is a novel technique for cancer treatent, it includes procedures of modifying patients' T cells outside the body and re-transfuse these cells back into the human body to fight against the cancer cells. |
Timeline
- Start date
- 2017-09-15
- Primary completion
- 2019-01-13
- Completion
- 2019-07-30
- First posted
- 2017-08-22
- Last updated
- 2019-02-15
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03258047. Inclusion in this directory is not an endorsement.